Gentian Diagnostics Management
Management criteria checks 3/4
Gentian Diagnostics' CEO is Njaal Kind, appointed in Apr 2024, has a tenure of less than a year. total yearly compensation is NOK3.04M, comprised of 71.1% salary and 28.9% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth NOK1.07M. The average tenure of the management team and the board of directors is 2 years and 2.2 years respectively.
Key information
Njaal Kind
Chief executive officer
NOK 3.0m
Total compensation
| CEO salary percentage | 71.1% |
| CEO tenure | less than a year |
| CEO ownership | 0.2% |
| Management average tenure | 2yrs |
| Board average tenure | 2.2yrs |
Recent management updates
Recent updates
Investors Appear Satisfied With Gentian Diagnostics ASA's (OB:GENT) Prospects As Shares Rocket 33%
Jun 29
Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report
Feb 14Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation
Oct 28We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn
May 11Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?
Mar 20What Percentage Of Gentian Diagnostics AS (OB:GENT) Shares Do Insiders Own?
Feb 21Have Insiders Been Selling Gentian Diagnostics AS (OB:GENT) Shares?
Jan 17
Gentian Diagnostics AS (OB:GENT): When Will It Breakeven?
Dec 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | NOK 2m |
| Jun 30 2024 | n/a | n/a | -NOK 2m |
| Mar 31 2024 | n/a | n/a | -NOK 6m |
| Dec 31 2023 | NOK 3m | NOK 2m | -NOK 11m |
| Sep 30 2023 | n/a | n/a | -NOK 5m |
| Jun 30 2023 | n/a | n/a | -NOK 14m |
| Mar 31 2023 | n/a | n/a | -NOK 18m |
| Dec 31 2022 | NOK 3m | NOK 2m | -NOK 24m |
| Sep 30 2022 | n/a | n/a | -NOK 29m |
| Jun 30 2022 | n/a | n/a | -NOK 26m |
| Mar 31 2022 | n/a | n/a | -NOK 26m |
| Dec 31 2021 | NOK 3m | NOK 2m | -NOK 25m |
| Sep 30 2021 | n/a | n/a | -NOK 19m |
| Jun 30 2021 | n/a | n/a | -NOK 19m |
| Mar 31 2021 | n/a | n/a | -NOK 17m |
| Dec 31 2020 | NOK 2m | NOK 2m | -NOK 17m |
| Sep 30 2020 | n/a | n/a | -NOK 21m |
| Jun 30 2020 | n/a | n/a | -NOK 19m |
| Mar 31 2020 | n/a | n/a | -NOK 38m |
| Dec 31 2019 | NOK 2m | NOK 2m | -NOK 40m |
Compensation vs Market: Njaal's total compensation ($USD266.84K) is about average for companies of similar size in the Norwegian market ($USD283.92K).
Compensation vs Earnings: Njaal's compensation has been consistent with company performance over the past year.
CEO
Njaal Kind
less than a year
Tenure
NOK 3,041,000
Compensation
Mr. Njaal Kind serves as Acting Chief Executive Officer since April 29, 2024 and Chief Financial Officer at Gentian Diagnostics AS and serves as its Chief Operating Officer. Mr. Kind has experience and ext...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairperson | less than a year | NOK 4.37m | 0.042% NOK 267.5k | |
| Acting CEO | less than a year | NOK 3.04m | 0.17% NOK 1.1m | |
| Chief Scientific Officer | 2yrs | NOK 1.90m | 0.013% NOK 82.0k | |
| Chief Commercial Officer | no data | NOK 2.83m | no data | |
| Head of Innovation & Research | 3yrs | no data | no data | |
| Head of Product Development | 3yrs | no data | no data |
2.0yrs
Average Tenure
Experienced Management: GENT's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairperson | less than a year | NOK 4.37m | 0.042% NOK 267.5k | |
| Independent Director | 2.7yrs | no data | no data | |
| Independent Director | no data | no data | 0.015% NOK 95.4k | |
| Independent Director | no data | no data | 0.11% NOK 697.0k | |
| Non-Executive Independent Director | 1.7yrs | no data | no data | |
| Non-Executive Director | 2.7yrs | no data | 0.18% NOK 1.2m |
2.2yrs
Average Tenure
59yo
Average Age
Experienced Board: GENT's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 09:20 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gentian Diagnostics ASA is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martinsson | DNB Markets |
| Geir Holom | DNB Markets |